An Evaluation of the Pharmacokinetics and Safety of LIPO-102 in Healthy Volunteers

Phase 1

Completed

• Conditions: Subcutaneous Adipose Tissue Reduction
• Interventions: Drug: LIPO-102

• Registration Number: NCT00918606
• Lead Sponsor: Neothetics, Inc

Brief Summary

An Evaluation of the PK and Safety of LIPO-102 in Healthy Volunteers.

Detailed Description

Not available

Study Timeline

• Study Start: 2009-02
• Primary Completion: 2009-06
• Study Completion: 2009-06
• Study First Submitted: 2009-06-10
• Study First Submitted QC: 2009-06-10
• Study First Posted: 2009-06-11
• Status Verified: 2015-03
• Last Update Submitted: 2015-03-19
• Last Update Posted: 2015-03-24

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

• Male and non pregnant female
• 18-55 years old
• Sufficient abdominal fat for injections
• Signed informed consent

Exclusion Criteria

• Known hypersensitivity to study drugs
• Treatment with an investigational agent within 30 days before first dose

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
LIPO-102	LIPO-102	-

Primary Outcome Measures

Name	Time	Method
Safety: Laboratory tests, medical exams	4 weeks

Secondary Outcome Measures

Name	Time	Method
Pharmacokinetics	24 hours